Dermata Therapeutics Files 8-K for Material Agreement

TL;DR

DRMA filed an 8-K for a material agreement on Jan 17th.

AI Summary

Dermata Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting a material definitive agreement entered into on January 17, 2025. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in San Diego, CA.

Why It Matters

This filing indicates a significant event for Dermata Therapeutics, likely involving a new contract or partnership that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, making the company's future performance uncertain.

Key Players & Entities

• Dermata Therapeutics, Inc. (company) — Registrant
• January 17, 2025 (date) — Date of earliest event reported
• January 21, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of Incorporation
• San Diego, CA (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share DRMA The Nasdaq Capital M

Filing Documents

• drma_8k.htm (8-K) — 35KB
• drma_ex101.htm (EX-10.1) — 194KB
• drma_ex991.htm (EX-99.1) — 30KB
• 0001654954-25-000570.txt ( ) — 455KB
• drma-20250117.xsd (EX-101.SCH) — 6KB
• drma-20250117_lab.xml (EX-101.LAB) — 16KB
• drma-20250117_cal.xml (EX-101.CAL) — 1KB
• drma-20250117_pre.xml (EX-101.PRE) — 12KB
• drma-20250117_def.xml (EX-101.DEF) — 4KB
• drma_8k_htm.xml (XML) — 6KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On January 17, 2025, Dermata Therapeutics, Inc. (the "Company") entered into a Clinical Trial Collaboration Agreement (the "Clinical Trial Agreement") with Revance Therapeutics, Inc. ("Revance"), pursuant to which the Company and Revance intend to conduct a multi-center clinical trial to evaluate the topical application of Xyngari, the Company's topical Spongilla powder (formerly referred to as DMT310), with Daxxify (daxibotulinumtoxinA-lanm), Revance's botulinum toxin type A. Under the Clinical Trial Agreement, the Company intends to sponsor, conduct and fund a Phase 2a clinical trial to evaluate the safety, tolerability and preliminary efficacy of Xyngari and Daxxify versus Xyngari and placebo in patients with moderate-to-severe axillary hyperhidrosis for 16 weeks (the "Trial"). The Trial is anticipated to be randomized (1:1:1:1), double-blind, placebo-controlled, and intends to enroll approximately 48 patients across sites in the United States. The endpoints are anticipated to be (i) the percent of patients with greater than 50% reduction in gravimetrically measured sweat production from baseline, (ii) the percent of patients with gravimetric sweat production less than 50mg, and (iii) the mean absolute change from baseline in gravimetrically measured sweat production. Patients are anticipated to be evaluated at four regular intervals. The Company and Revance will form a joint development committee to facilitate communications between the parties related to the Trial. Pursuant to the terms of the Clinical Trial Agreement, Revance has granted the Company a non-exclusive, worldwide, non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use certain Revance intellectual property, solely as necessary or useful for the Company to conduct the trial under the Clinical Trial Agreement. The Company has granted Revance a similar license to use Xyngari and other compound(s)

Forward-Looking Statements

Forward-Looking Statements

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 21, 2025, the Company issued a press release announcing its entry into the Clinical Trial Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Clinical Trial Collaboration Agreement 99.1 Press Release, dated January 21, 2025, issued by Dermata Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DERMATA THERAPEUTICS, INC. Dated: January 21, 2025 By: /s/ Gerald T. Proehl Gerald T. Proehl Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR